Hospital

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Fibroadenoma may feel like a marble in the breast, moving easily under the skin when examined.

Sarah Temkin, MD, of the Office of Research on Women’s Health at the National Institutes of Health, discusses some key points for pharmacists on the impact of biological and sociological variables on treatment outcomes.

Tom Hanzel, PharmD, MBA, discussed how vaccine mandates impact staffing shortages in long-term care facilities.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Chemotherapy-induced nausea and vomiting can impact patients’ treatment outcomes.

According to a Kaiser Permanente research study, individuals who received COVID-19 vaccination had lower non-COVID-19 death rates than individuals who were unvaccinated.

Tom Hanzel, PharmD, MBA, of Parata Systems, discussed challenges in pharmacy workflow and how automation could offer solutions.

They can create innovative face-to-face and virtual medication therapy management practices.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses some of NIH ORWH’s upcoming goals and projects on the horizon that may impact the pharmacy field.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.

More transparent drug pricing could improve patient care.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, discusses how clinical trials have evolved to address biological and sociological variables in patient health.

The FDA looks to address a lack of diversity in cancer drug trials.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.

Andrew Mulcahy, PhD, a senior policy researcher at RAND Corporation, discusses a recent report that showed the drug shortages in the United States may not be associated with problems in the global supply chain.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses how the diabetes DRIVE program compares with the SHC DRIVE models for flu and COVID-19 vaccinations.

Chronic hypersensitivity pneumonitis is a long-term lung condition in which the interstitial tissue surrounding the alveoli of the lungs becomes inflamed and develops fibrosis.

Trial court judge places limits on testimony of widow’s pharmacy expert witness and dismisses lawsuit.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses what the SHC’s diabetes DRIVE toolkit is and how it helps to address disparities in diabetes disease burden and health outcomes.

Sarah Temkin, MD, of the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the NIH ORWH has helped to advance clinical research on biological and sociological variables.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.

David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Bladder cancer risk increases with age and is more common among men than women.

Study suggests that emergency physicians prescribe naloxone to patients who overdose.

Common triggers for atrial fibrillation include alcohol, caffeine, and less sleep.